

IFU

PATENT
Attorney Docket No.: 057309-5004-US02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Robert BARGATZE <i>et al.</i>)	
)	
Application No. 10/780,650)	Art Unit: 1653
)	
Filed: February 19, 2004)	Examiner: Not Assigned
)	
For: IDENTIFICATION OF PATHOGEN-LIGAND)	
INTERACTIONS)	

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, **Mail Stop Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants petition the Examiner to consider this Information Disclosure Statement and documents listed on the attached PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

Copies of the listed documents are enclosed. These documents were cited in an opposition request in the European application that corresponds to the parent of the present application. Applicants respectfully request that the Examiner consider the listed documents and indicate that the documents have been considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies the document as "prior art" against any claims in the application and Applicants determine that the cited document does not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or to credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Dated: **February 1, 2005**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, NW
Washington, D.C. 20004
Telephone: (202) 739-3000
Facsimile: (202) 739-3001

Respectfully submitted,
Morgan, Lewis & Bockius LLP



Bonnie Weiss McLeod
Registration No. 43,255



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket No. 057309-5004-US02		Application No. 10/780,650	
PTO Form 1449				Applicants: Robert BARGATZE <i>et al.</i>		PAGE 1 of 1	
				Filing Date: February 19, 2004		Group Art Unit: 1653	
U.S. PATENT DOCUMENTS							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
	1.	5,175,096	12/29/1992	Hook et al.	435	69.1	05/09/1990
	2.	5,189,015	02/23/1993	Hook et al.	514	2	12/05/1991
	3.	5,320,951	06/14/1994	Hook et al.	435	69.1	01/22/1993
	4.	5,416,021	05/16/1995	Hook et al.	435	252.33	09/23/1993
	5.	5,440,014	08/08/1995	Hook et al.	530	326	04/28/1994
FOREIGN PATENT DOCUMENTS							
		Document No.	Date	Country	Class	Sub-Class	Translation
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	6.	Beachy (1981) J Infect Dis 143(5), 325-345					
	7.	Bleiweis et al. (1992) Adv Exp Med Biol 327, 229-241					
	8.	Brassart et al. (1991) Infection and Immunity 59(5), 1605-1613					
	9.	Burgess and McDonald (1992) Infection and Immunity 60(10), 4254-4259					
	10.	Dean-Nystrom and Samuel (1994) Infection and Immunity 62(11), 4789-4794					
	11.	Finlay and Falkow (1989) Microbial Reviews 53(2), 210-230					
	12.	Hoepelman and Tuomanen (1992) Infection and Immunity 60(5), 1729-1733					
	13.	Jacobs et al. (1987) J Bacteriol 169(2), 735-741					
	14.	Johnson (1991) Clinical Microbiology Reviews 4(1), 80-128					
	15.	Kavoon et al. (1994) Ukr Biokhim Zh 66(2), 90-93 (Pubmed abstract only)					
	16.	Mamo et al. (1994) Immunol Med Microbiol 10(1), 47-52					
	17.	McGarey et al. (1994) Infection and Immunity 62(10), 4594-4601					
	18.	Payne et al. (1993) Infection and Immunity 61(9), 3673-3677					
	19.	Petri and Ravdin (1991) Infection and Immunity 59(1), 97-101					
	20.	Prasad et al. (1993) Infection and Immunity 61(7), 2780-2785					
	21.	Raja et al. (1990) Infection and Immunity 58(8), 2593-2598					
	22.	Ravdin (1989) J Infect Dis 159(3), 420-429					
	23.	Ravdin et al. (1986) Infection and Immunity 53(1), 1-5					
	24.	Rozdzinske et al. (1993) J Exp Med 178, 917-924					
	25.	Rozdzinski et al. (March 1995) J Clin Invest 95, 1078-1085					
	26.	Saukkonen et al. (1992) PNAS 89, 118-122					
	27.	Soong et al. (March 1995) J Infect Dis 171(3), 645-651					
	28.	Tham et al. (1994) J Bacteriol 176(3), 781-788					
	29.	Wu et al (December 1995) Infection and Immunity 63(12), 4933-4938					
Examiner				Date Considered			
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							